KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Quest Diagnostics (DGX) EBIAT (2016 - 2025)

Quest Diagnostics' EBIAT history spans 17 years, with the latest figure at $271.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 14.83% year-over-year to $271.0 million; the TTM value through Dec 2025 reached $1.0 billion, up 13.57%, while the annual FY2025 figure was $1.0 billion, 13.57% up from the prior year.
  • EBIAT for Q4 2025 was $271.0 million at Quest Diagnostics, up from $259.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $631.0 million in Q2 2021 and bottomed at $113.0 million in Q4 2022.
  • The 5-year median for EBIAT is $247.5 million (2022), against an average of $297.2 million.
  • The largest annual shift saw EBIAT soared 346.23% in 2021 before it plummeted 76.21% in 2022.
  • A 5-year view of EBIAT shows it stood at $475.0 million in 2021, then tumbled by 76.21% to $113.0 million in 2022, then soared by 117.7% to $246.0 million in 2023, then decreased by 4.07% to $236.0 million in 2024, then rose by 14.83% to $271.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's EBIAT are $271.0 million (Q4 2025), $259.0 million (Q3 2025), and $296.0 million (Q2 2025).